In context
Research, regulation, safety and market around peptides - briefly contextualized and sourced.
48 posts ·continuously updated ·independent & ad-free
Symbolic image A new Chainalysis report reveals the gray-market peptide crypto ecosystem has surpassed $100 million annually, with former fentanyl precursor suppliers entering the space and independent safety testing collapsing.
Symbolic image A prespecified analysis of the SELECT trial (The Lancet, October 2025) reveals that semaglutide reduces major adverse cardiovascular events by 20% - and this benefit is largely independent of baseline weight or amount of weight…
Symbolic image The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, effectively ending large-scale compounding of these GLP-1 drugs.
Symbolic image US poison control centers report a 1,500 % surge in calls about GLP-1 drugs, the class behind popular weight-loss and diabetes medications like Ozempic, Wegovy and Mounjaro, since 2019. The rise is driven by dosing errors with compounded versions of semaglutide and tirzepatide (custom-mixed imitations prepared by special pharmacies rather than the original manufacturer, and not subject to standard
Symbolic image Eli Lilly's triple agonist retatrutide achieved up to 28.3 % weight loss in the Phase 3 TRIUMPH trials - the highest ever recorded in a Phase 3 GLP-1-class study.
Symbolic image The EMA has recommended approval of Wegovy tablets (oral semaglutide) for weight management - a first for GLP-1 therapy in pill form. Here's what it means for patients and the market.
Symbolic image The European Medicines Agency (EMA) and national authorities warn of a sharp rise in falsified GLP-1 products - while the UK MHRA tightens safety advice on pancreatitis risks for all GLP-1 receptor agonists.
Symbolic image BPC-157 and GHK-Cu are among the most popular peptides, yet their evidence bases could hardly be more different: GHK-Cu has decades of research behind it, while BPC-157 still lacks a single completed randomized human trial.
Symbolic image FDA, TGA, and HPRA are warning against Melanotan II: The unapproved tanning peptide can cause melanoma, priapism, and brain swelling - despite an ongoing TikTok trend. An overview of the documented dangers.
The Peptide Signal - monthly, ad-free Learn more